Legend Biotech (NASDAQ:LEGN - Get Free Report) is expected to post its quarterly earnings results before the market opens on Tuesday, March 11th. Analysts expect Legend Biotech to post earnings of ($0.34) per share and revenue of $179.00 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.
Legend Biotech Trading Up 2.2 %
LEGN stock traded up $0.75 during midday trading on Friday, hitting $34.93. The stock had a trading volume of 622,793 shares, compared to its average volume of 1,177,042. The firm has a market cap of $6.38 billion, a PE ratio of -36.71 and a beta of 0.19. The company's 50-day moving average price is $35.30 and its 200 day moving average price is $41.81. Legend Biotech has a 12-month low of $30.17 and a 12-month high of $69.24. The company has a debt-to-equity ratio of 0.27, a current ratio of 4.98 and a quick ratio of 4.90.
Analyst Upgrades and Downgrades
LEGN has been the subject of a number of recent research reports. Royal Bank of Canada reiterated an "outperform" rating and issued a $86.00 target price on shares of Legend Biotech in a research note on Monday, December 9th. Piper Sandler reaffirmed an "overweight" rating and set a $78.00 target price on shares of Legend Biotech in a research report on Monday, December 30th. HC Wainwright restated a "buy" rating and set a $73.00 price objective on shares of Legend Biotech in a report on Tuesday, January 21st. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $83.00 price target on shares of Legend Biotech in a research note on Monday, December 9th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $79.50.
View Our Latest Report on LEGN
Legend Biotech Company Profile
(
Get Free Report)
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).
Further Reading
Before you consider Legend Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Legend Biotech wasn't on the list.
While Legend Biotech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
